2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Revenue | $34M | $44M | $38M | $42M | $49M |
Cost of Revenue | $9.7M | $12M | $10M | $11M | $11M |
Gross Profit | $24M | $32M | $27M | $31M | $38M |
Gross Profit % | 71% | 73% | 73% | 73% | 77% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Net Income | -$1.7M | $3.7M | -$10M | $14M | $6.1M |
Dep. & Amort. | $11M | $12M | $14M | $15M | $19M |
Def. Tax | $389K | -$388K | $3.4M | -$19M | -$1.8M |
Stock Comp. | $350K | $261K | $532K | $1.1M | $1.5M |
Chg. in WC | -$1.7M | $2M | $1.9M | $689K | -$49K |
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Cash | $8.6M | $5.9M | $28M | $150M | $52M |
ST Investments | $17M | $1M | $0 | $0 | $0 |
Cash & ST Inv. | $26M | $6.9M | $28M | $150M | $52M |
Receivables | $6M | $6.6M | $254K | $713K | $2.8M |
Inventory | $2.7M | $2.1M | $0 | $0 | -$6.4M |
Order intake grew 5% in total, with 1% organic growth despite uncertain market conditions, with strong demand from pharmaceutical production, process industry, and energy sectors.
Net sales increased 4% in total, with organic sales flat; EBITA margin was 13.6% (13.3% excluding one-offs), with record high gross margin for Q1.
Cash flow improved 32% year-over-year to SEK 644 million, with continued improvement in working capital efficiency and a low net debt to EBITDA ratio of 1.3.
Three acquisitions completed so far in 2025 with annual turnover of $390 million; acquisition pipeline remains strong with the company in a solid financial position.
Many companies are now actively working to align costs to market conditions due to increased market volatility following April 2nd tariff announcements, though direct US exposure is limited at less than 6% of group sales.